my understanding is that “under the radar” just means not actively approaching and shopping the company with big pharma - that’ll be done in a concentrated roadshow once management have collected a little bit more data.
I think there is (and definitely should be) normal investor relations activities like talking to these kinds of funds going on. @RaceOncology should be able to confirm that (not market sensitive IMO - talking to investors and explaining the company’s potential and plans is expected of public companies like Race). The run up in price before a buyout is going to be driven by many more retail investors and perhaps some of these funds buying in.
Industry news, page-15
-
- There are more pages in this discussion • 1,843 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.37 |
Change
-0.170(11.1%) |
Mkt cap ! $232.5M | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.48 | $1.36 | $632.2K | 451.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 76 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 4136 | 2 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |